Biotechnology News and Research

RSS

Results from Puma’s PB272 Phase I combination trial on metastatic HER-2 positive breast cancer

Puma Biotechnology, Inc., a development stage biopharmaceutical company, announced that results from an ongoing Phase I clinical trial of its lead drug candidate PB272 (neratinib) given in combination with the anticancer drugs paclitaxel and trastuzumab in patients with metastatic HER-2 positive breast cancer were presented in a poster presentation at the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting.

4 Jun 2012

Data from several clinical trials of ADCETRIS to be presented at ASCO annual meeting

Seattle Genetics, Inc. today announced that data from several clinical trials of ADCETRIS (brentuximab vedotin) will be presented at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 1-5, 2012 in Chicago, IL.

4 Jun 2012

Genentech’s T-DM1 Phase III study on HER2-positive mBC meets primary endpoint

Genentech, a member of the Roche Group, today announced that the Phase III EMILIA study of trastuzumab emtansine (T-DM1) met its co-primary endpoint of a significant improvement in the time people with HER2-positive metastatic breast cancer (mBC) lived without their disease getting worse (progression-free survival, PFS).

4 Jun 2012

Final results from ArQule and Daiichi Sankyo’s tivantinib phase 2 trial on HCC

ArQule, Inc. and Daiichi Sankyo Co., Ltd. today announced final results from a randomized, placebo-controlled, double-blind, phase 2 clinical trial with the selective MET inhibitor tivantinib as a single-agent, investigational, second-line treatment in hepatocellular carcinoma (HCC).

4 Jun 2012

Roche to initiate three studies with T-DM1 for early stage HER2-positive breast cancer

ImmunoGen, Inc., a biotechnology company with a proprietary Targeted Antibody Payload (TAP) technology, today announced that Roche is implementing a "three-pronged approach" to developing trastuzumab emtansine (T-DM1) for early stage HER2-positive breast cancer, according to plans outlined by Roche at its 2012 ASCO analyst event.

4 Jun 2012

Engineered proteins demonstrate flu-fighting potency

Computer-designed proteins are under construction to fight the flu. Researchers are demonstrating that proteins found in nature, but that do not normally bind the flu, can be engineered to act as broad-spectrum antiviral agents against a variety of flu virus strains, including H1N1 pandemic influenza.

2 Jun 2012

Global generic pharmaceuticals market to reach $231.00 billion in 2017 at 9.29% CAGR

The global generic pharmaceuticals market is likely to witness strong growth in the next few years owing to the patent expiration of key blockbuster drugs and the judicious cost containment efforts of governments and healthcare service providers worldwide.

2 Jun 2012

America's biopharmaceutical researchers work on many new approaches to fight cancer

America's biopharmaceutical research companies are testing 981 medicines and vaccines to fight the many types of cancer affecting millions of patients worldwide, according to a report released today by the Pharmaceutical Research and Manufacturers of America.

2 Jun 2012

Amarantus to announce results from preclinical study of new protein therapy for TBI

Rainbow BioSciences, the biotech subsidiary of Rainbow Coral Corp., announced today that its latest joint venture target, Amarantus BioSciences, Inc., expects to announce the results of a preclinical study evaluating the potential of its new protein therapy as a treatment for Traumatic Brain Injury (TBI).

2 Jun 2012

Affymetrix, Leica Microsystems enter worldwide collaboration on RNA ISH analysis

Affymetrix, Inc. and Leica Microsystems are pleased to announce a world-wide collaboration that automates Affymetrix' QuantiGene ViewRNA ISH Tissue Assay on the Leica BOND RX staining platform for research applications.

1 Jun 2012

CINJ wins renewal of Comprehensive Cancer Center designation from NCI

The Cancer Institute of New Jersey (CINJ) has been awarded renewal of its Comprehensive Cancer Center designation from the National Cancer Institute.

1 Jun 2012

New Lupus Insight Prize to be awarded to outstanding investigator

Lupus organizations have come together to launch a first-of-a-kind initiative to encourage scientific advances in lupus research.

1 Jun 2012

Kindstar, Insight Genetics collaborate to improve cancer care in China

Molecular diagnostics company Insight Genetics and Kindstar Globalgene Technology, Inc., China's leading diagnostics company, today announced that the companies are partnering to enhance cancer care in the People's Republic of China and surrounding regions.

1 Jun 2012

Researchers devise strategy to directly activate natural ‘death’ protein

Researchers at Dana-Farber/Children's Hospital Cancer Center have devised a strategy to directly activate a natural "death" protein, triggering the self-destruction of cells. They say the development could represent a new paradigm for designing cancer drugs.

1 Jun 2012

Vitamin D3 supplements could provide more health benefits

New research funded by the Biotechnology and Biological Sciences Research Council (BBSRC) has shown that vitamin D3 supplements could provide more benefit than the close relative vitamin D2.

1 Jun 2012

ForteBio introduces new biosensor for use on Octet and BLItz instrumentation platforms

ForteBio, a division of Pall Life Sciences and a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the introduction of its Dip and Read Ni-NTA biosensor for use on its Octet and BLItz instrumentation platforms.

1 Jun 2012

Oncothyreon commences PX-866 and vemurafenib Phase 1/2 combination trial for melanoma

Oncothyreon Inc. today announced the initiation of a Phase 1/2 trial of PX-866 in combination with vemurafenib.

1 Jun 2012

RXi’s RXI-109 IND receives FDA clearance to proceed into clinical trials

RXi Pharmaceuticals Corporation today announced that it has received clearance for its investigational new drug application (IND) from the U.S. Food and Drug Administration (FDA) to initiate clinical trials with RXI-109, a self-delivering RNAi compound that selectively targets Connective Tissue Growth Factor.

1 Jun 2012

Life Technologies, OpGen enter collaboration on Whole Genome Mapping and Ion Torrent sequencing

Life Technologies Corporation and OpGen, Inc., a commercial stage whole genome analysis company, today announced that they have signed a collaboration agreement to develop systems, technologies and applications intended to improve the management and surveillance of microbial outbreaks in the public health and infectious disease markets.

31 May 2012

External LED light source for Endolume announced by Lighthouse Imaging

Lighthouse Imaging Corporation now offers the L700, an external LED light source, as a companion product to its Endolume endoscope system light tester. This inexpensive light source, when used in conjunction with Endolume, provides the necessary illumination to enable biomedical technicians, clinical engineers, and endoscope service technicians to quantitatively test the illumination characteristics of the endoscopic system.

31 May 2012

Biotechnology News and Research

Results from Puma’s PB272 Phase I combination trial on metastatic HER-2 positive breast cancer

Data from several clinical trials of ADCETRIS to be presented at ASCO annual meeting

Genentech’s T-DM1 Phase III study on HER2-positive mBC meets primary endpoint

Final results from ArQule and Daiichi Sankyo’s tivantinib phase 2 trial on HCC

Roche to initiate three studies with T-DM1 for early stage HER2-positive breast cancer

Engineered proteins demonstrate flu-fighting potency

Global generic pharmaceuticals market to reach $231.00 billion in 2017 at 9.29% CAGR

America's biopharmaceutical researchers work on many new approaches to fight cancer

Amarantus to announce results from preclinical study of new protein therapy for TBI

Affymetrix, Leica Microsystems enter worldwide collaboration on RNA ISH analysis

CINJ wins renewal of Comprehensive Cancer Center designation from NCI

New Lupus Insight Prize to be awarded to outstanding investigator

Kindstar, Insight Genetics collaborate to improve cancer care in China

Researchers devise strategy to directly activate natural ‘death’ protein

Vitamin D3 supplements could provide more health benefits

ForteBio introduces new biosensor for use on Octet and BLItz instrumentation platforms

Oncothyreon commences PX-866 and vemurafenib Phase 1/2 combination trial for melanoma

RXi’s RXI-109 IND receives FDA clearance to proceed into clinical trials

Life Technologies, OpGen enter collaboration on Whole Genome Mapping and Ion Torrent sequencing

External LED light source for Endolume announced by Lighthouse Imaging

Biotechnology eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News